| AbTech Overview | ||||||||||||||||||||||||||||||||
Abmart offers academic researchers, clinicians and product developers revolutionary technologies for fast, successful and cost-efficient discovery, detection and functional manipulation of proteins and chemical molecules.?? Our long-term goal is to create an antibody democracy so that anyone with any molecule in mind can have desired monoclonal antibodies, successfully and affordably. Our technology starts with our technology team.? We have assembled a talented and passionate group of scientists in Shanghai to develop unique and powerful new antibody technologies.? This group (called AbX™ within the company), consisting of biologists, physicists, computer scientists, chemists and technologists, is dedicated to solving important antibody problems with novel ideas and approaches.? AbX™ team members are ambitious, hard-working and practical.? Their work in the past few years have produced game-changing antibody products such as 30 day monoclonal antibodies ( UrgentMab™ series based on PETAL™ technology) and functional monoclonal antibodies for challenging protein targets (ion channels) ( SEAL™ series based on SEAL™). |
||||||||||||||||||||||||||||||||
|
Our antibody technology “ecosystem” consists of the following components (Table 1)
|
||||||||||||||||||||||||||||||||
Together, these technologies enable much faster, more cost-effective, many times more successful and at a much larger scale for monoclonal antibody discovery, a fundamental activity with an ever increasing importance. |
||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||
| AbTech platforms |
|
We have developed two revolutionary technologies, SEAL™and PETAL™, for much faster, much more successful and even more cost-effective monoclonal antibody discovery than any previous approaches. Traditional antibody approaches only probe a small fraction of surface sequences of a target protein due to high cost and research-like nature of antibody development.? Our monoclonal antibody assembly line has achieved industrialized, high quality, high success rate and low cost antibody development. So we have developed two antibody technologies to take advantage of these features to offer an unparallel opportunity to explore protein surface sequences thoroughly with a large number of antibodies against all surface sequences, many times over. This shot-gun, library approach ( SEAL™) has proven to be highly productive to identify functional sites of a protein for antibody targeting (Cell 157, 1393 C404, 2014) .? To greatly cut down the time for monoclonal antibody development, we are launching PETAL™-based product, AbX™, for developing monoclonal antibodies in about 30 days, roughly 20% of traditional method, while still delivering high affinity, specific antibodies. SEAL™ for functional and detection antibody development for difficult targets ? SEAL™(Surface Epitope Antibody Library) is a library approach for deep coverage of a protein target with a large library of monoclonal antibodies against a large library of protein surface antigens.? SEAL™ consists of novel technologies for antigen design, potent immunogen preparation, efficient animal immunization, and large-scale antibody screening to produce high affinity, highly specific antibodies.? SEAL™ has proven to be a successful approach for developing antibodies for difficult applications (flow cytometry, IHC, IP and functional) against difficult targets such as membrane proteins (GPCRs, ion channels), transcription factors and signaling molecules.? Further, we have built an industrialized monoclonal antibody assembly line for making SEAL™ antibodies so that the unit cost for each antibody development is only at a small fraction of traditional approaches.? Together, SEAL™ offers an unprecedented freedom and success for monoclonal antibody discovery. PETAL™for ultra-fast, ultra low cost monoclonal antibody discovery To enable monoclonal antibody generation in weeks rather than months (from sequence), we have developed PETAL™ (Proteome Epitope Tag Antibody Library), a proprietary, pre-made monoclonal antibody library with close to 50,000 mouse monoclonal antibodies against more than 20,000 peptide antigens representative of millions of proteins across hundreds of species.? For a target protein, multiple (typically 5-30) peptide antigens are designed and synthesized to screen the PETAL™ library (arrayed on chips).? Screening results of 5000 peptide antigens (derived from more than 400 proteins representative of more than 100 species) demonstrate that there 60 out of 100 peptide antigens can yield an average of 2 high affinity (dot blot detection sensitivity <1 ng, comparable to a FLAG antibody) monoclonal antibodies.? So it is guaranteed to discover antibodies against a target if >=4 peptide antigens are used for library screening.? Peptide synthesis and screening takes about 4-6 weeks.? PETAL™ offers a revolutionary way (we call this product AbX, for express, exploration or any target) for monoclonal antibody discovery for any protein target from any species.? Furthermore, we have priced AbX at a price similar to catalog antibodies so that everyone is able to afford to access PETAL™ for monoclonal antibody discovery.?? |
|
Proteome Research We have developed two revolutionary technologies, Mabome™and MabArray™, for proteome-scale monoclonal antibody discovery and differential protein profiling . Despite the importance of affinity proteomics in basic and applied research,? it has not been widely adopted due to a lack of affinity reagents, particularly monoclonal antibodies.? The formidable cost and research-like nature of traditional antibody approaches make it impractical for proteome-scale antibody development.?? Our monoclonal antibody assembly line has achieved industrialized, high quality, high success rate and low cost antibody development. So we have developed two proteome-scale antibody technologies to take advantage of these features to offer an unparallel opportunity to probe a proteome. Mabomics™ for proteome-scale monoclonal antibody development? Mabome™ (monoclonal antibody omics) develops monoclonal antibodies for thousands of expressed proteins in a proteome (biological sample).? A protein sample (for example, plasma; or a tissue; or a cellular organelle) is processed to produce protein and peptide fractions as immunogens.? A set of proprietary mouse monoclonal antibody technologies is employed to produce 10,000-100,000 individual mouse hybridomas to cover a significant portion (typically 30-70%) of the proteome.? Thus produced Mabome™ libraries have broad applications in differential proteomics and reagent development. MabArray™ antibody arrays for profiling thousands of cell surface and blood proteins MabArray™ is a massively parallel, proprietary antibody array platform with 10,000-30,000 pre-made monoclonal antibodies (using Mabome™ technology) against diverse protein complexes including total cellular proteins, specific cellular organelle proteins (cell surface, and nuclear proteins) and plasma proteins.? MabArray™ has proven to be able to measure thousands of cell surface and blood proteins.? MabArray™ provides unbiased, high coverage profiling of expressed proteomes of cells, tissues and body fluids to enable high-throughput and efficient disease biomarkers and therapeutic targets discovery. |
|
Chemical Immunology Despite its importance, monoclonal antibodies against small molecules including metabolites, drugs (antibiotics, chemotherapeutic drugs) and agricultural chemicals (pesticides) are difficult and expensive to develop. We have developed a proprietary process (SMAL™) for affordable and productive monoclonal antibody discovery for small molecules.? SMAL™ for high-success monoclonal antibody development against chemical molecules Similar to the library approach of SEAL™, SMAL™ starts with a combinatorial chemical antigen library (CCAL) design based on the specific structural features of a target chemical molecule.? CCAL typically consists of multiple chemical modifications of the target molecule so that different immunogenic and unique chemical groups are guaranteed to be exposed for generating antibodies. Thus produced CCAL is then going through the potent immunogen generation technology (VLP) developed at Abmart for high affinity and specific monoclonal antibody generation. SMAL™ has proven to be effective for antibody development against diverse chemicals, thus providing key building blocks (antibodies) for building immunoassay-based detection of important small molecules. |